Table 3.

Event rates for primary and secondary end points according to treatment time (either all hypertension medications upon awakening or ≥1 medication at bedtime)

VariableaAwakeningb (n = 332)Bedtimeb (n = 329)P between groupsc
Primary end points
    Total events57.9 (48.6 to 67.1); 10419.8 (13.6 to 26.0); 35<0.001
    Major events14.5 (9.1 to 19.8); 265.1 (1.8 to 8.4); 9<0.001
Secondary end points
    Total death7.8 (3.8 to 11.8); 144.0 (1.0 to 6.8); 70.056
        Cardiovascular death3.9 (1.0 to 6.8); 71.1 (0.0 to 2.7); 20.059
        Other cause3.9 (1.0 to 6.8); 72.8 (0.4 to 5.3); 50.758
    Cardiovascular events26.1 (19.2 to 33.1); 476.2 (2.6 to 9.8); 11<0.001
        Myocardial infarction8.9 (4.7 to 13.2); 162.8 (0.4 to 5.3); 50.005
        Angina pectoris10.0 (5.5 to 1.45); 181.7 (0.1 to 3.6); 3<0.001
        Revascularization7.2 (3.4 to 11.1); 131.7 (0.1 to 3.6); 30.004
    Cerebrovascular events2.2 (0.3 to 4.4); 41.1 (0.0 to 2.7); 20.310
        Heart failure15.0 (9.6 to 20.5); 274.5 (1.4 to 7.6); 8<0.001
        Other events6.7 (3.0 to 10.4); 120.0 (1.0 to 6.8); 70.119
  • a Total events include the following: death (from all causes), cardiovascular events (myocardial infarction, angina pectoris, and coronary revascularization), cerebrovascular events (stroke and transient ischemic attack), heart failure, and other events (acute arterial occlusion of lower extremities and thrombotic occlusion of the retinal artery). Major events include the following: cardiovascular deaths, myocardial infarction, ischemic stroke, and hemorrhagic stroke.

  • b Event rates (with 95% CIs in parentheses, followed by the actual number of events) are expressed as the number/1000 patient-years, i.e., a ratio of the observed number of events to the total number of patient-years of exposure.

  • c Comparison of event rates between treatment time groups was done by the Mantel log-rank test.